Liu Mei, Song Xiang-Zhun, Yang Liu, Fang Yu-Hui, Lan Liu, Cui Jing-Shu, Lu Xiao-Chen, Zhu Hai-Yang, Quan Lin-Hu, Han Hong-Mei
Department of Gastroenterology, Affiliated Hospital of Yanbian University, Yanji, Jilin, China.
Department of Gastroenterology, Jilin Provincial People's Hospital, Changchun, Jilin, China.
Front Endocrinol (Lausanne). 2025 Mar 21;16:1528768. doi: 10.3389/fendo.2025.1528768. eCollection 2025.
We studied the potential protective effects of 1,25-dihydroxyvitamin D3 (1,25 VD3) supplementation on liver damage induced by a choline-deficient (CD) diet in rats, where impaired liver function leads to decreased 25-hydroxyvitamin D3 levels, the precursor for the active 1,25 VD3. The CD diet reduced serum 25 VD3 levels and increased liver enzymes, indicative of liver damage. Conversely, 1,25 VD3 supplementation alleviated liver damage, reducing liver enzymes and improving histopathological features characteristic of non-alcoholic steatohepatitis (NASH). Oxidative stress and inflammation were mitigated by 1,25 VD3, as evidenced by decreased malondialdehyde and nuclear factor kappa B (NF-κB) expression, and increased total antioxidant capacity (TAOC). 1,25 VD3 also enhanced fatty acid metabolism by increasing peroxisome proliferator-activated receptor alpha (PPARα) and carnitine palmitoyltransferase-1 (CPT-1) expression, promoting lipid transport and oxidation. Additionally, 1,25 VD3 supplementation modulated inflammation by increasing PPARγ expression, reducing NF-κB expression, and decreasing pro-inflammatory cytokines (TNF-α, IL-1β). Anti-inflammatory cytokines (IL-10, IL-4) were increased, and macrophage polarization was shifted towards an anti-inflammatory M2 phenotype. Moreover, 1,25 VD3 upregulated CYP2J3, a cytochrome P450 epoxygenase that converts arachidonic acid to anti-inflammatory epoxyeicosatrienoic acids (EETs) and decreased soluble epoxide hydrolase activity, likely contributing to increased EET levels. Correlation studies revealed positive associations between 1,25 VD3 supplementation, CYP2J3 expression, EETs, as well as negative correlations with NF-κB and TNF-α. PPARα expression positively correlated with TAOC and CPT-1, while PPARγ expression negatively correlated with inflammatory markers. These findings demonstrate the therapeutic potential of 1,25 VD3 in alleviating NASH through regulation of fatty acid metabolism, inflammation, and oxidative stress.
我们研究了补充1,25 - 二羟基维生素D3(1,25 VD3)对胆碱缺乏(CD)饮食诱导的大鼠肝损伤的潜在保护作用,在这种情况下,肝功能受损会导致活性1,25 VD3的前体25 - 羟基维生素D3水平降低。CD饮食降低了血清25 VD3水平并升高了肝酶,这表明存在肝损伤。相反,补充1,25 VD3减轻了肝损伤,降低了肝酶并改善了非酒精性脂肪性肝炎(NASH)的组织病理学特征。1,25 VD3减轻了氧化应激和炎症,丙二醛和核因子κB(NF - κB)表达降低以及总抗氧化能力(TAOC)增加证明了这一点。1,25 VD3还通过增加过氧化物酶体增殖物激活受体α(PPARα)和肉碱棕榈酰转移酶 - 1(CPT - 1)的表达来增强脂肪酸代谢,促进脂质转运和氧化。此外,补充1,25 VD3通过增加PPARγ表达、降低NF - κB表达以及减少促炎细胞因子(TNF - α、IL - 1β)来调节炎症。抗炎细胞因子(IL - 10、IL - 4)增加,巨噬细胞极化转变为抗炎M2表型。此外,1,25 VD3上调了CYP2J3,一种细胞色素P450环氧化酶,它将花生四烯酸转化为抗炎环氧二十碳三烯酸(EETs)并降低可溶性环氧化物水解酶活性,这可能导致EET水平升高。相关性研究揭示了补充1,25 VD3、CYP2J3表达、EETs之间的正相关,以及与NF - κB和TNF - α之间的负相关。PPARα表达与TAOC和CPT - 1呈正相关,而PPARγ表达与炎症标志物呈负相关。这些发现证明了1,25 VD3通过调节脂肪酸代谢、炎症和氧化应激来减轻NASH的治疗潜力。